Table 3.
Prevalence and adjusted ORs for thrombophilia among women with VTE
| Excluding women | |||||
| with malignancy, | |||||
| recent surgery or | |||||
| All women | immobilization* | ||||
| Number (%) | Number (%) | ||||
| of cases with | controls with | ||||
| thrombophilia | thrombophilia | Crude OR | Adjusted OR† | Adjusted OR‡ | |
| Thrombophilia factor | factor | factor | (95% CI) | (95% CI) | (95% CI) |
| Prothrombin (++ or +/-) | 12 (9.3) | 3 (2.3) | 4.3 (1.2-15.6) | 4.3 (1.1-17.4) | 7.8 (1.0-64.2) |
| Factor V (+/+ or +/-) | 21 (16.3) | 5 (3.9) | 4.8 (1.8-13.2) | 3.9 (1.4-10.8) | 3.6 (1.2-11.4) |
| MTHFR C677T (+/+) | 19 (14.7) | 13 (10.1) | 1.5 (0.7-3.3) | 1.4 (0.6-3.1) | 1.1 (0.4-2.9) |
| MTHFR 1298C (+/+) | 68 (52.7) | 69 (53.5) | 1.0 (0.6-1.6) | 1.0 (0.6-1.7) | 1.2 (0.6-2.3) |
| MTRR A66G (+/+) | 42 (32.6) | 35 (27.1) | 1.3 (0.8-2.2) | 1.1 (0.6-2.2) | 0.9 (0.4-2.2) |
| Any MTHFR (+/+) or A66G MTRR (+/+) | 90 (69.8) | 88 (68.2) | 1.1 (0.6-1.8) | 1.0 (0.6-2.0) | 1.1 (0.5-2.3) |
| Fasting plasma hyperhomocysteinemia$ | 46 (35.6) | 5 (4.0) | 13.7 (5.2-36.0) | 17.8 (4.2-74.9) | 11.6 (2.7-50.5) |
*Excludes cases with immobilization or surgery within the past 3 months, or a malignancy within the past 5 years, and their respective control individuals. †Adjusted for cigarette smoking, oestrogen exposure state and recent history of cancer. ‡Adjusted for cigarette smoking and oestrogen exposure state. $Defined as a homocysteine concentration greater than the 95th centile value in the control group. +/+, Homozygous; +/-, heterozygous.